• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A new player in psoriatic arthritis: a JAK inhibitor.

作者信息

Sakkas Lazaros I

机构信息

Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.

出版信息

Mediterr J Rheumatol. 2017 Dec 22;28(4):210-211. doi: 10.31138/mjr.28.4.210. eCollection 2017 Dec.

DOI:10.31138/mjr.28.4.210
PMID:32185285
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7045999/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1854/7045999/32186ecb7bf8/MJR-28-4-210-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1854/7045999/32186ecb7bf8/MJR-28-4-210-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1854/7045999/32186ecb7bf8/MJR-28-4-210-g001.jpg

相似文献

1
A new player in psoriatic arthritis: a JAK inhibitor.银屑病关节炎的新参与者：一种JAK抑制剂。
Mediterr J Rheumatol. 2017 Dec 22;28(4):210-211. doi: 10.31138/mjr.28.4.210. eCollection 2017 Dec.
2
Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis.JAK抑制剂治疗银屑病和银屑病关节炎的疗效与安全性：一项系统评价和荟萃分析。
BMC Rheumatol. 2022 Sep 27;6(1):71. doi: 10.1186/s41927-022-00287-7.
3
New JAK inhibitors for the treatment of psoriasis and psoriatic arthritis.新型 JAK 抑制剂治疗银屑病和银屑病关节炎。
G Ital Dermatol Venereol. 2020 Aug;155(4):411-420. doi: 10.23736/S0392-0488.20.06658-4. Epub 2020 Jun 15.
4
Tofacitinib for the treatment of psoriasis and psoriatic arthritis.托法替布治疗银屑病和银屑病关节炎。
G Ital Dermatol Venereol. 2020 Aug;155(4):400-410. doi: 10.23736/S0392-0488.20.06643-2. Epub 2020 Apr 29.
5
English version of Japanese guidance for the use of oral Janus kinase inhibitors (JAK1 and TYK2 inhibitors) in the treatments of psoriasis.日本指导意见的英文版本，用于口服 Janus 激酶抑制剂（JAK1 和 TYK2 抑制剂）治疗银屑病。
J Dermatol. 2023 May;50(5):e138-e150. doi: 10.1111/1346-8138.16797. Epub 2023 Apr 1.
6
Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis.性别相关的患者特征差异，以及在随机临床试验中接受高级治疗的银屑病关节炎患者的疗效和安全性：系统文献回顾和荟萃分析。
Lancet Rheumatol. 2023 Dec;5(12):e716-e727. doi: 10.1016/S2665-9913(23)00264-3. Epub 2023 Nov 14.
7
Recent developments for new investigational JAK inhibitors in psoriatic arthritis.新型 JAK 抑制剂在银屑病关节炎中的研究进展。
Expert Opin Investig Drugs. 2023 May;32(5):361-371. doi: 10.1080/13543784.2023.2207737. Epub 2023 May 3.
8
JAK Inhibitors in Psoriatic Disease.银屑病疾病中的JAK抑制剂
Clin Cosmet Investig Dermatol. 2023 Oct 31;16:3129-3145. doi: 10.2147/CCID.S433367. eCollection 2023.
9
Performance of Janus kinase inhibitors in psoriatic arthritis with axial involvement in indirect comparison with ankylosing spondylitis: a retrospective analysis from pooled data.与强直性脊柱炎间接比较时，JAK抑制剂在伴有轴向受累的银屑病关节炎中的疗效：一项基于汇总数据的回顾性分析
Clin Rheumatol. 2021 May;40(5):1725-1737. doi: 10.1007/s10067-020-05442-4. Epub 2020 Oct 17.
10
Tofacitinib for the treatment of psoriasis and psoriatic arthritis.托法替布治疗银屑病和银屑病关节炎。
Expert Rev Clin Immunol. 2018 Sep;14(9):719-730. doi: 10.1080/1744666X.2018.1512404.

引用本文的文献

1
Mediterranean Journal of Rheumatology December 2017 Highlights.《地中海风湿病学杂志》2017年12月亮点。
Mediterr J Rheumatol. 2017 Dec 22;28(4):169-170. doi: 10.31138/mjr.28.4.169. eCollection 2017 Dec.

本文引用的文献

1
Magnetic resonance imaging (MRI) of feet demonstrates subclinical inflammatory joint disease in cutaneous psoriasis patients without clinical arthritis.磁共振成像（MRI）显示足部有亚临床炎症性关节病的皮肤银屑病患者无临床关节炎。
Clin Rheumatol. 2018 Feb;37(2):383-388. doi: 10.1007/s10067-017-3895-z. Epub 2017 Dec 4.
2
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.托法替布或阿达木单抗与安慰剂治疗银屑病关节炎的比较。
N Engl J Med. 2017 Oct 19;377(16):1537-1550. doi: 10.1056/NEJMoa1615975.
3
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
托法替布治疗对 TNF 抑制剂应答不足的银屑病关节炎患者。
N Engl J Med. 2017 Oct 19;377(16):1525-1536. doi: 10.1056/NEJMoa1615977.
4
Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data.银屑病和银屑病关节炎是同一种疾病吗？IL-23/IL-17 轴数据。
Autoimmun Rev. 2017 Jan;16(1):10-15. doi: 10.1016/j.autrev.2016.09.015. Epub 2016 Sep 22.
5
Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study.皮下注射司库奇尤单抗在根据既往肿瘤坏死因子抑制剂使用情况分层的活动性银屑病关节炎患者中的疗效：随机安慰剂对照FUTURE 2研究结果
J Rheumatol. 2016 Sep;43(9):1713-7. doi: 10.3899/jrheum.160275. Epub 2016 Jun 15.
6
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.银屑病关节炎研究与评估小组 2015 年银屑病关节炎治疗建议。
Arthritis Rheumatol. 2016 May;68(5):1060-71. doi: 10.1002/art.39573. Epub 2016 Mar 23.
7
European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.欧洲抗风湿病联盟（EULAR）药物治疗银屑病关节炎管理建议：2015 年更新。
Ann Rheum Dis. 2016 Mar;75(3):499-510. doi: 10.1136/annrheumdis-2015-208337. Epub 2015 Dec 7.
8
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.抗白细胞介素-12/23 p40 单克隆抗体乌司奴单抗治疗常规非生物和生物抗肿瘤坏死因子治疗失败的活动性银屑病关节炎患者的疗效和安全性：III 期、多中心、双盲、安慰剂对照、随机 PSUMMIT 2 试验的 6 个月和 1 年结果。
Ann Rheum Dis. 2014 Jun;73(6):990-9. doi: 10.1136/annrheumdis-2013-204655. Epub 2014 Jan 30.
9
Enthesitis in psoriatic arthritis.银屑病关节炎的附着点炎。
Semin Arthritis Rheum. 2013 Dec;43(3):325-34. doi: 10.1016/j.semarthrit.2013.04.005. Epub 2013 May 31.
10
Janus kinases in immune cell signaling.免疫细胞信号传导中的 Janus 激酶
Immunol Rev. 2009 Mar;228(1):273-87. doi: 10.1111/j.1600-065X.2008.00754.x.